<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00014508</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000068551</org_study_id>
    <secondary_id>ECOG-E4A98</secondary_id>
    <nct_id>NCT00014508</nct_id>
  </id_info>
  <brief_title>Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma</brief_title>
  <official_title>A Phase II Trial Of Autologous Stem Cell Transplant Followed By Mini-Allogeneic Stem Cell Transplant In Lieu Of Standard Allogeneic Bone Marrow Transplantation For Treatment Of Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eastern Cooperative Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Eastern Cooperative Oncology Group</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing&#xD;
      so they stop growing or die. Peripheral stem cell transplantation may be able to replace&#xD;
      immune cells that were destroyed by chemotherapy. Sometimes the transplanted cells are&#xD;
      rejected by the body's tissues. Peripheral stem cell transplantation with the person's own&#xD;
      stem cells followed by donor peripheral stem cell transplantation may prevent this from&#xD;
      happening.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of combining chemotherapy with autologous&#xD;
      peripheral stem cell transplantation and donor peripheral stem cell transplantation in&#xD;
      treating patients who have multiple myeloma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the incidence of early mortality in patients with multiple myeloma treated&#xD;
           with melphalan and autologous peripheral blood stem cell (PBSC) transplantation followed&#xD;
           by fludarabine, cyclophosphamide, and allogeneic PBSC transplantation.&#xD;
&#xD;
        -  Determine the incidence of early allogeneic graft failure (before day 100 after&#xD;
           allogeneic PBSC transplantation) and the incidence of severe acute graft-versus-host&#xD;
           disease (GVHD) in patients treated with this regimen.&#xD;
&#xD;
        -  Determine the toxicity of this regimen in these patients.&#xD;
&#xD;
        -  Determine the overall and disease-free survival of patients treated with this regimen.&#xD;
&#xD;
        -  Correlate changes in the T-cell population with clinical outcome, such as survival, in&#xD;
           patients treated with this regimen.&#xD;
&#xD;
        -  Correlate changes in the T-cell population with the incidence of GVHD, use of&#xD;
           immunosuppressive agents, and effects of fludarabine in patients treated with this&#xD;
           regimen.&#xD;
&#xD;
        -  Determine the degree of chimerism after allogeneic PBSC transplantation and the time&#xD;
           course over which it is established in patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive melphalan IV over 15 minutes on day -1. Autologous peripheral blood stem&#xD;
      cells (PBSCs) are reinfused on day 0. Patients also receive sargramostim (GM-CSF)&#xD;
      subcutaneously (SC) or IV over at least 30 minutes daily beginning on day 1 and continuing&#xD;
      until blood counts recover. Beginning 100-182 days after autologous PBSC transplantation,&#xD;
      patients receive fludarabine IV over 30 minutes on days -6 to -2 and cyclophosphamide IV over&#xD;
      1-2 hours on days -3 and -2. Allogeneic PBSCs are infused on day 0. Patients may receive a&#xD;
      second allogeneic PBSC infusion on day 1. Patients also receive GM-CSF SC or IV over at least&#xD;
      30 minutes daily beginning on day 1 and continuing until blood counts recover. Cyclosporine&#xD;
      is administered IV or orally twice daily as graft-versus-host disease (GVHD) prophylaxis,&#xD;
      beginning on day -1 and continuing until day 60, followed by a taper in the absence of GVHD.&#xD;
&#xD;
      Patients are followed for 5 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total 19-46 patients will be accrued for this study within 3 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2001</start_date>
  <completion_date type="Actual">May 27, 2011</completion_date>
  <primary_completion_date type="Actual">February 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Multiple Myeloma and Plasma Cell Neoplasm</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>sargramostim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclosporine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine phosphate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melphalan</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of multiple myeloma meeting 1 of the following criteria:&#xD;
&#xD;
               -  Bone marrow plasmacytosis with at least 10% plasma cells&#xD;
&#xD;
               -  Sheets of plasma cells&#xD;
&#xD;
               -  Biopsy-proven plasmacytoma&#xD;
&#xD;
          -  Meets at least 1 of the following criteria:&#xD;
&#xD;
               -  Presence of myeloma (M)-protein in the serum&#xD;
&#xD;
               -  Presence of M-protein in the urine&#xD;
&#xD;
               -  Radiographic evidence of osteolytic lesions&#xD;
&#xD;
                    -  Generalized osteoporosis allowed if at least 20% plasma cells in bone marrow&#xD;
&#xD;
          -  No non-secretory myeloma&#xD;
&#xD;
               -  Prior M-protein in serum or urine allowed provided patient is now in complete&#xD;
                  remission&#xD;
&#xD;
          -  Must be receiving conventional-dose chemotherapy as initial therapy or as salvage&#xD;
             therapy&#xD;
&#xD;
          -  Must have HLA-A, -B, and -DR genotypically identical sibling donor&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 to 70&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  AST no greater than 3 times upper limit of normal&#xD;
&#xD;
          -  Bilirubin less than 2.0 mg/dL&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  LVEF greater than 40% at rest if symptomatic cardiac disease is present&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  DLCO greater than 50% of predicted (corrected for hemoglobin) if symptomatic pulmonary&#xD;
             disease is present&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  No prior autologous or allogeneic peripheral blood stem cell or bone marrow&#xD;
             transplantation&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  More than 28 days since prior chemotherapy (including primary chemotherapy for&#xD;
             hematopoietic stem cell collection)&#xD;
&#xD;
          -  No other concurrent cytotoxic chemotherapy between autologous and allogeneic&#xD;
             transplantation&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Prior dexamethasone or other corticosteroids allowed&#xD;
&#xD;
          -  Concurrent corticosteroids between autologous and allogeneic transplantation allowed&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  Concurrent radiotherapy between autologous and allogeneic transplantation allowed&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Neal Flomenberg, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Sidney Kimmel Cancer Center at Thomas Jefferson University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Baptist Cancer Institute - Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207-8554</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic - Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center at Tufts - New England Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Cancer Center</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Northern New Jersey</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MBCCOP-Our Lady of Mercy Cancer Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10466</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ireland Cancer Center at University Hospitals of Cleveland and Case Western Reserve University</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106-5065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MetroHealth's Cancer Care Center at MetroHealth Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn State Cancer Institute at Milton S. Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033-0850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abramson Cancer Center at the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Vesole DH, Zhang L, Flomenberg N, Greipp PR, Lazarus HM, Huff CA; ECOG Myeloma and BMT Committees. A Phase II trial of autologous stem cell transplantation followed by mini-allogeneic stem cell transplantation for the treatment of multiple myeloma: an analysis of Eastern Cooperative Oncology Group ECOG E4A98 and E1A97. Biol Blood Marrow Transplant. 2009 Jan;15(1):83-91. doi: 10.1016/j.bbmt.2008.10.030. Erratum in: Biol Blood Marrow Transplant. 2009 Oct;15(10):1346. Huff, Carol A [added].</citation>
    <PMID>19135946</PMID>
  </reference>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>April 10, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>December 30, 2018</last_update_submitted>
  <last_update_submitted_qc>December 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 2, 2019</last_update_posted>
  <keyword>refractory multiple myeloma</keyword>
  <keyword>stage I multiple myeloma</keyword>
  <keyword>stage II multiple myeloma</keyword>
  <keyword>stage III multiple myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Sargramostim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

